Overall, these findings show that strong cooperation between TFs OCT4 and SOX2 (and a peptide derived from it) is important for binding to their specific enhancer sites and for the high levels of expression of OCT4/SOX2 in carcinomas and ESCs, with both factors providing great promise for therapeutic applications. The gene discussed is POU5F1; the disease is carcinoma.